Efficacy of Combination Therapy with the JAK Inhibitor Baricitinib in the Treatment of COVID-19
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2523-8973
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Efficacy of Combination Therapy with the JAK Inhibitor Baricitinib in the Treatment of COVID-19 ; volume:4 ; number:1 ; day:21 ; month:1 ; year:2022 ; pages:1-13 ; date:12.2022
SN comprehensive clinical medicine ; 4, Heft 1 (21.1.2022), 1-13, 12.2022
- Urheber
-
Thoms, Brendan L.
Gosselin, Jeanne
Libman, Bonita
Littenberg, Benjamin
Budd, Ralph C.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s42399-022-01121-4
- URN
-
urn:nbn:de:101:1-2022050219000610146477
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:37 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Thoms, Brendan L.
- Gosselin, Jeanne
- Libman, Bonita
- Littenberg, Benjamin
- Budd, Ralph C.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Baricitinib in der klinischen Routine - ein interdisziplinärer Erfahrungsaustausch : JAK-Inhibition bei atopischer Dermatitis
Ein Jahr Praxiserfahrung mit Baricitinib : der erste orale JAK-Inhibitor bei atopischer Dermatitits
Baricitinib reduces inflammation and improves cell homeostasis of HGPS fibroblasts by inhibiting JAK-STAT signaling
Efficacy and drug persistence of baricitinib monotherapy is similar to combination therapy in patients with active RA: a prospective observational study
Impact of JAK inhibitors tofacitinib and baricitinib on bone turnover during steady-state and pathological conditions
Efficacy of Baricitinib in Patients with Refractory Adult-Onset Still’s Disease
The effect of JAK inhibitors baricitinib and tofacitinib on Th17 cells, regulatory T cells and the Th17/Treg balance in patients with rheumatoid arthritis
Efficacy and Safety of Baricitinib in Chinese Rheumatoid Arthritis Patients and the Subgroup Analyses: Results from Study RA-BALANCE
Baricitinib blocks cytokine mediated downregulation of PAD1 in human keratinocytes: a possible molecular link to the effects of JAK-inhibitors in atopic dermatitis
Cost-Effectiveness of Combination of Baricitinib and Remdesivir in Hospitalized Patients with COVID-19 in the United States: A Modelling Study
Efficacy and safety of baricitinib for the treatment of hospitalized adults with COVID-19: a systematic review and meta-analysis
Safety and Efficacy of Baricitinib in Patients Receiving Conventional Synthetic Disease-Modifying Antirheumatic Drugs or Corticosteroids
Baricitinib in der klinischen Routine - ein interdisziplinärer Erfahrungsaustausch : JAK-Inhibition bei atopischer Dermatitis
Ein Jahr Praxiserfahrung mit Baricitinib : der erste orale JAK-Inhibitor bei atopischer Dermatitits
Baricitinib reduces inflammation and improves cell homeostasis of HGPS fibroblasts by inhibiting JAK-STAT signaling
Efficacy and drug persistence of baricitinib monotherapy is similar to combination therapy in patients with active RA: a prospective observational study
Impact of JAK inhibitors tofacitinib and baricitinib on bone turnover during steady-state and pathological conditions
Efficacy of Baricitinib in Patients with Refractory Adult-Onset Still’s Disease
The effect of JAK inhibitors baricitinib and tofacitinib on Th17 cells, regulatory T cells and the Th17/Treg balance in patients with rheumatoid arthritis
Efficacy and Safety of Baricitinib in Chinese Rheumatoid Arthritis Patients and the Subgroup Analyses: Results from Study RA-BALANCE
Baricitinib blocks cytokine mediated downregulation of PAD1 in human keratinocytes: a possible molecular link to the effects of JAK-inhibitors in atopic dermatitis
Cost-Effectiveness of Combination of Baricitinib and Remdesivir in Hospitalized Patients with COVID-19 in the United States: A Modelling Study
Efficacy and safety of baricitinib for the treatment of hospitalized adults with COVID-19: a systematic review and meta-analysis
Safety and Efficacy of Baricitinib in Patients Receiving Conventional Synthetic Disease-Modifying Antirheumatic Drugs or Corticosteroids
Baricitinib in der klinischen Routine - ein interdisziplinärer Erfahrungsaustausch : JAK-Inhibition bei atopischer Dermatitis
Ein Jahr Praxiserfahrung mit Baricitinib : der erste orale JAK-Inhibitor bei atopischer Dermatitits
Baricitinib reduces inflammation and improves cell homeostasis of HGPS fibroblasts by inhibiting JAK-STAT signaling
Efficacy and drug persistence of baricitinib monotherapy is similar to combination therapy in patients with active RA: a prospective observational study
Impact of JAK inhibitors tofacitinib and baricitinib on bone turnover during steady-state and pathological conditions
Efficacy of Baricitinib in Patients with Refractory Adult-Onset Still’s Disease
The effect of JAK inhibitors baricitinib and tofacitinib on Th17 cells, regulatory T cells and the Th17/Treg balance in patients with rheumatoid arthritis
Efficacy and Safety of Baricitinib in Chinese Rheumatoid Arthritis Patients and the Subgroup Analyses: Results from Study RA-BALANCE
Baricitinib blocks cytokine mediated downregulation of PAD1 in human keratinocytes: a possible molecular link to the effects of JAK-inhibitors in atopic dermatitis
Cost-Effectiveness of Combination of Baricitinib and Remdesivir in Hospitalized Patients with COVID-19 in the United States: A Modelling Study
Efficacy and safety of baricitinib for the treatment of hospitalized adults with COVID-19: a systematic review and meta-analysis